Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Popat, Rakesh [1 ]
Richardson, Paul G. [2 ]
Trudel, Suzanne [3 ]
Quach, Hang [4 ]
Lonial, Sagar [5 ]
Orlowski, Robert Z. [6 ]
Kim, Kihyun [7 ]
Mateos, Maria-Victoria [8 ]
Pawlyn, Charlotte [9 ,10 ]
Ramasamy, Karthik [11 ]
Martinez-Lopez, Joaquin [12 ]
Casas-Aviles, Ignacio [13 ]
Spirli, Alessia [14 ]
Gong, Jing [15 ]
Amatangelo, Michael [15 ]
Katz, Jessica [15 ]
Maciag, Paulo [15 ]
Peluso, Teresa [14 ]
Bahlis, Nizar J. [16 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia
[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[7] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[8] Univ Hosp Salamanca, IBSAL, Salamanca, Spain
[9] Royal Marsden NHS Fdn, London, England
[10] Inst Canc Res, London, England
[11] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England
[12] Univ Complutense Madrid, Hosp Octubre, Hosp 12 Octubre, Dept Hematol,CIBERONC, Madrid, Spain
[13] Hosp San Pedro Alcantara, Caceres, Spain
[14] Celgene Int Sarl Bristol Myers Squibb Co, Boudry, Switzerland
[15] Bristol Myers Squibb, Princeton, NJ USA
[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-PO15
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [41] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [42] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [43] Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment
    Weisel, Katja
    Dimopoulos, Meletios A.
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Kueenburg, Elisabeth
    Lersch, Frederik
    Rosettani, Barbara
    Bacon, Pamela
    Sonneveld, Pieter
    BLOOD, 2016, 128 (22)
  • [44] Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.
    Dhakal, Binod
    D'souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos Eduardo
    Schroeder, Katrina
    Gauger, Katelyn
    Crone, Karen
    Pasquini, Marcelo C.
    Chhabra, Saurabh
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
    van de Donk, Niels W. C. J.
    Raab, Marc S.
    Besemer, Britta
    Siegel, David S.
    Anwer, Faiz
    Lipe, Brea
    White, Darrell
    Khan, Abdullah
    Pianko, Matthew J.
    Cheng, Yiming
    Chen, Lu
    Lin, Hongxia
    Maciag, Paulo
    Emerson, Joshua
    Amin, Alpesh
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S191 - S192
  • [46] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Quach, Hang
    Vorobyev, Vladimir I.
    Cavo, Michele
    Suzuki, Kazuhito
    Robak, Pawel
    Morris, Kristin
    Phillips-Jones, Amy
    Zhou, Xiaoou Linnette
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
  • [47] Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Zonder, Jeffrey A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Stephens, Leonor A.
    McDonnell, Kathryn
    Uribe, Rebecca
    Rosebeck, Shaun
    Rashal, Tami
    Youssoufian, Hagop
    Henry, Sarah
    Shacham, Sharon
    Kauffman, Michael
    Zimmerman, Todd
    Karrison, Theodore
    BLOOD, 2015, 126 (23)
  • [48] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [49] Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
    Niesvizky, Ruben
    Costa, Luciano J.
    Haideri, Nisreen A.
    Hess, Georg
    Singhal, Seema
    Spicka, Ivan
    Stadtmauer, Edward A.
    Badros, Ashraf Z.
    Raab, Marc S.
    Jakubczak, John L.
    Kim, Sindy T.
    Randolph, Sophia
    Ely, Scott A.
    Chen-Kiang, Selina
    BLOOD, 2011, 118 (21) : 1268 - 1269
  • [50] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
12345